Clinical Trials · NCT01618513

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

CompletedPhase 4Octreotide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
University of Aarhus
Enrollment
84
Start date
Jun 2012
Locations
1 site, Denmark
Primary endpoint
Change in Quality of Life
View Octreotide compound reference